FDA Faces Court Deadline on Mifepristone Review as Drug Used in Over Two-Thirds of Abortions
Updated
Updated · POLITICO · Oct 7
FDA Faces Court Deadline on Mifepristone Review as Drug Used in Over Two-Thirds of Abortions
1 articles · Updated · POLITICO · Oct 7
Summary
A federal judge in Louisiana ordered the FDA to report Wednesday on the status of its internal review of mifepristone, forcing rare disclosure about a process the agency has kept largely opaque.
The filing stems from lawsuits challenging Biden-era rules that let the abortion pill be prescribed by telehealth and mailed to patients; the Trump administration has largely tried to dismiss or pause those cases on standing grounds until the review ends.
Anti-abortion groups say the FDA is moving too slowly and hiding its work, while abortion-rights advocates call the effort a sham review aimed at restricting a drug with an extensive safety record.
The outcome could reshape access to mifepristone for millions of people, including in states that ban abortion and those that protect it, while leaving the Trump administration exposed to backlash from both sides before the midterms.
What hidden details in the FDA's private review could permanently alter how millions access telehealth medications?
How might a single court ruling on this medication disrupt future medical research for fibroids and endometriosis nationwide?
The Future of Medication Abortion: How Legal Battles Over Mifepristone Threaten Access for 65% of U.S. Abortions
Overview
The FDA’s October 7, 2026 update on mifepristone comes amid intense political and legal pressure, with a federal judge’s deadline driving the agency’s ongoing safety review. Political shifts and anti-abortion advocacy accelerated the review, while the Trump administration delayed final decisions until after the midterms. If the Fifth Circuit rules for Louisiana, nationwide telehealth and mail-order access to mifepristone would halt, forcing patients to travel for care and creating major barriers, especially for rural and vulnerable populations. This legal battle threatens not only abortion access but also the FDA’s authority, as states and courts challenge science-based drug approvals, risking broader impacts on healthcare and drug development.